Prostate cancer: Towards the standardization and synthesis of morphology, genetics, and prognosis

Histopathology

Volumn 60, Issue 1, 2012, Pages 1-3

  Berney, Dan ^a   Cheng, Liang ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetics; Morphology; Prognosis; Prostate cancer

Indexed keywords

GENETICS; HISTOPATHOLOGY; HUMAN; MEDICAL RESEARCH; MORPHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; STANDARDIZATION; SYNTHESIS;

HUMANS; MALE; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE STANDARDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84255199237     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04080.x     Document Type: Review

References (22)

1. Eeles RA, Kote-Jarai Z, Al Olama AA et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 2009; 41; 1116-1121.
2. Mao X, Yu Y, Boyd LK et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res. 2010; 70; 5207-5212.
3. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310; 644-648.
4. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009; 360; 1310-1319.
5. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009; 360; 1320-1328.
6. Ahmed HU, Zacharakis E, Dudderidge T et al. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br. J. Cancer 2009; 101; 19-26.
7. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 2005; 29; 1228-1242.
8. Egevad L, Srigley JR, Delahunt B. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens: rationale and organization. Mod. Pathol. 2011; 24; 1-5.
9. Delahunt BM, Miller RJ, Srigley JR, Evans AJ, Samaratunga H. Gleason grading, past, present and future. Histopathology 2012; 60; 75-86.
10. Egevad L. Handling of radical prostatectomy specimens. Histopathology 2012; 60; 118-124.
11. Epstein JI. Diagnosis of limited adenocarcinoma of the prostate. Histopathology 2012; 60; 28-40.
12. Montironi R, Scarpelli M, Mazzucchelli R, Cheng L, Lopez-Beltran A. The spectrum of morphology in non-neoplastic prostate including cancer mimics. Histopathology 2012; 60; 41-58.
13. Humphrey PA. Histologic variants of prostate carcinoma and their significance. Histopathology 2012; 60; 59-74.
14. Paner G, Aron M, Hansel D, Amin MB. Non-epithelial neoplasms of the prostate. Histopathology 2012; 60; 166-186.
15. Cheng L, Montironi R, Bostwick D, Lopez-Beltran A, Berney DM. Staging of prostate cancer. Histopathology 2012; 60; 87-117.
16. Srigley JR, Delahunt B, Evans AJ. Therapy-associated effects in the prostate gland. Histopathology 2012; 60; 153-165.
17. Fine SW, Reuter VE. Anatomy of the prostate revisited: implications for prostate biopsy and zonal origins of prostate cancer. Histopathology 2012; 60; 142-152.
18. Bostwick DG, Cheng L. Precursors of prostate cancer. Histopathology 2012; 60; 4-27.
19. Sfanos K, DeMarzo A. Prostate cancer and inflammation: the evidence. Histopathology 2012; 60; 199-215.
20. Kristiansen G. Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 2012; 60; 125-141.
21. Barbieri C, Demichelis F, Rubin MA. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 2012; 60; 187-198.
22. Gleave M. Targeted therapy in prostate cancer. Histopathology 2012; 60; 216-231.